Drug intelligence / Profile preview

aibenatide

Development stage: Unknown
Lead developer: Changshan Biochemical Pharmaceutical
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

**Aibenatide** is a novel once-weekly GLP-1 receptor agonist under development for type 2 diabetes. It demonstrates significant hypoglycemic effects and weight loss at lower doses compared to existing therapies, administered subcutaneously for patient convenience. Phase I/II clinical trials are completed, with Phase III ongoing as of 2021; it is developed by an unnamed Chinese innovator aiming for rapid market penetration post-approval.

Other names: ibenatide

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on aibenatide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on aibenatide.

Explore the full profile